Abstracts tagged "Sjogren’s syndrome and biomarkers"

Abstract Number: 2880 • 2018 ACR/ARHP Annual Meeting
Serum Levels of Thymic Stromal Lymphopoietin: A Possible Novel Biomarker in Primary Sjögren’s Syndrome and Related Lymphoproliferation
Saviana Gandolfo¹, Cinzia Fabro¹, Michela Bulfoni², Elena Doriguzzi Breatta¹, Daniela Cesselli², Carla Di Loreto² and Salvatore De Vita¹, ¹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ²Institute of Anatomic Pathology, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy
Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been demonstrated to be involved in B-cell lymphoproliferation and lymphoma mainly by tissue studies on salivary glands (SG) biopsies…
Abstract Number: 2194 • 2012 ACR/ARHP Annual Meeting
Cathepsin S Activity in Tears As a Marker of Sjögren’s Syndrome
S.E. Whitt¹, K. Renduchintala¹, S. Janga², M. Shah², J. Zhu³, K. Silka³, S. Bricel³, D. Bach³, M. Heur⁴, S. Christianakis⁵, J. Irvine⁴, D. Arkfeld⁶, W.J. Mack³, William Stohl⁷ and S.F. Hamm-Alvarez², ¹University of Southern California Keck School of Medicine -These authors contributed equally to this work, Los Angeles, CA, ²University of Southern California School of Pharmacy, Los Angeles, CA, ³University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Doheny Eye Institute, Los Angeles, CA, ⁵Med/Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶Div of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁷Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Currently used biomarkers for Sjögren’s Syndrome (SS), such as anti-SSA/Ro or anti-SSB/La, lack sensitivity and specificity. The goal of the work presented here…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].